OS Therapies Terminates Equity Line of Credit @ostherapies #Chemicals #Biotechnology #Investing
New York, New York--(Newsfile Corp. - August 25, 2025) - OS Therapies Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, today announced that it terminated its Equity Purchase Agreement (the "ELOC") with Square Gate Capital Master Fund, LLC — Series 3, effective August 26, 2025. "The recent success of our warrant exercise inducement and exchange offering provided the Company with $4.2 million in...
http://dlvr.it/TMhLpJ
http://dlvr.it/TMhLpJ
Comments
Post a Comment